We are excited to present our study on clinical utility of on-treatment PSMA PET in identifying sites of residual disease and in treatment interruption, with prolonged treatment-free intervals in a subset of patients. @HJacene@DanaFarber_GU@thomashopemdclinical-genitourinary-cance…
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨
@CACancerJournal
📋 Average risk: PSA every 2 yrs, ages 50-69
📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69
📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69
🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy
🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs
⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69
🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010
🔗 doi.org/10.3322/caac.70112@UroOnc@urotoday@UrologyTimes@PCF_Science@AmerUrological
#EMUC26 webcasts are up!
Are we creating long-term survivors or long-term patients? Is lifelong systemic therapy for recurrent/metastatic prostate cancer warranted?
The MSKCC Genitourinary Oncology Service is looking for a motivated, patient-centered, clinical investigator with a focus on urothelial cancer. Join a great team focused on eradicating GU cancers!
msk.wd108.myworkdayjobs.com/…
Super insightful piece. With Daniel Sentana and @CaPsurvivorship, we’ve had similar debates re the meaning of healthcare contact days in advanced prostate cancer.
"Ultimately, time is the most precious thing any person has—never more so than after a cancer diagnosis—and protecting how it is spent is a goal worth our shared effort."
Our piece - The commodification of Time Toxicity In Oncology
ascopubs.org/doi/10.1200/JCO…
Fair points, nicely laid out.
With ADT, my top Q is: Does giving ADT now buy this patient sufficiently lower risk of something worse down the road?
If 6m ADT with MDT only delays need for ADT in the future, that’s not good enough. Needs to ⬇️death or ⬆️treatment-free survival.
🌟 Past and current @BIDMC_HOFellows presented at #ASCOQLTY26, including work led by @JRusheen implementing a BILH-wide tobacco screening and cessation referral program.
Updated LUNAR analysis out in @EUplatinum. Now with a median follow-up of 32 months, exploratory analyses confirm the addition of 177Lu-PNT2002 to SBRT improves polymetastatic PFS (6 or more new lesion), castrate disease-free survival, and CT-based PFS (i.e., conventional MFS) authors.elsevier.com/sd/arti…